Nxera Pharma Expands QUVIVIQ® Reach in Asia-Pacific via Synmosa Deal
Event summary
- Nxera Pharma has granted Synmosa exclusive rights to commercialize QUVIVIQ® (daridorexant) in eight Asia-Pacific markets, including Singapore, Thailand, and Australia.
- Synmosa will lead regulatory approvals, market access, and sales, while Nxera will supply the drug product and receive upfront payments, milestones, and royalties.
- The deal expands QUVIVIQ®'s potential access in the region, building on existing progress in Japan, Taiwan, and South Korea.
- QUVIVIQ® is a dual orexin receptor antagonist developed by Idorsia Pharmaceuticals for treating insomnia in adults.
The big picture
This agreement is part of Nxera Pharma's strategy to expand access to innovative specialty medicines across Japan and the broader Asia-Pacific region. The deal with Synmosa, a specialty pharmaceutical company with strong regional capabilities, underscores the growing focus on insomnia treatments in emerging markets. The success of this partnership could set a precedent for similar collaborations in the region.
What we're watching
- Regulatory Progress
- The pace at which Synmosa secures regulatory approvals in the eight Asia-Pacific markets will determine the timeline for QUVIVIQ®'s commercial launch.
- Market Penetration
- Whether Synmosa can effectively leverage its regional platform to drive market access and sales in diverse markets like Indonesia and Vietnam.
- Revenue Impact
- How the upfront payments, milestones, and royalties from this deal will contribute to Nxera Pharma's financial performance in the coming years.
Related topics
